기본 정보
- 표준 SMILES
CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl- InChIKey
KPBZROQVTHLCDU-UHFFFAOYSA-N- 분자식
- C21H23Cl2NO6
- 평균 분자량
- 456.3 g/mol
- 단동위원소 질량
- 455.09024282
개요
Clevidipine is a dihydropyridine.
이름 및 식별자
- 우선 이름
- 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-((1-oxobutoxy)methyl) ester
- IUPAC
- 5-O-(butanoyloxymethyl) 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
- 영어명
- Clevidipine
- 분자식
- C21H23Cl2NO6
- 분자량
- 456.32
이름 및 동의어
이름 더 보기
데이터베이스 식별자
- CAS
166432-28-6、167221-71-8- PubChem CID
- 153994
- DTXSID
DTXSID6057661- ChEMBL
CHEMBL1237132- ChEBI
CHEBI:135738- UNII
- 19O2GP3B7Q
- EC Number
- 682-702-2、814-032-5
- Nikkaji
- J772.200A
물성
구조 계산 물성
- XLogP
- 4.3
- 극성 표면적
- 90.9 Ų
- 수소 결합 공여자 수
- 1
- 수소 결합 수용자 수
- 7
- 회전 가능 결합 수
- 10
- 무거운 원자 수
- 30
- 형식 전하
- 0
- 복잡도
- 748
실험 및 물리화학적 성질
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
물리화학적 성질
- 녹는점
- 137 · 137-139°C
- 저장 조건
- Refrigerator
- 용해도
- DMSO(약간 용해됨), 메탄올(약간 용해됨)
- 물리적 상태
- 고체
- 색상
- 흰색에서 황백색까지
안전 및 규제
GHS 분류
GHS Classification
Danger
H301 (33.3%): Toxic if swallowed [Danger Acute toxicity, oral]
P203, P260, P264, P270, P280, P301+P316, P308+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Warning
H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
유해성 정보
Hazard Classes and Categories
Acute Tox. 3 (33.3%)
Repr. 2 (100%)
독성 정보
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Clevidipine
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
안전 데이터
- 신호 어
- Warning
- 유해·위험 문구
- 암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H361
화학 및 산업
약리 정보
ATC Code
C08CA16
C - Cardiovascular system
QC - Cardiovascular system
Pharmacodynamics
Clevidipine belongs to a well-known class of drugs called dihydropyridine calcium channel antagonists. Clevidpine is the first third generation intravenous dihydropyridine calcium channel blocker. In vitro studies demonstrated that clevidipine acts by selectively relaxing the smooth muscle cells that line small arteries, resulting in arterial dilation, widening of the artery opening, and without reducing central venous pressure or reducing cardiac output.
Mechanism of Action
Possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, clevidipine inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. The resultant inhibition of the contractile processes of the myocardial smooth muscle cells leads to dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue.
FDA Pharmacological Classification
19O2GP3B7Q
CLEVIDIPINE
Mechanisms of Action [MoA] - Calcium Channel Antagonists
Established Pharmacologic Class [EPC] - Dihydropyridine Calcium Channel Blocker
Chemical Structure [CS] - Dihydropyridines
Clevidipine is a Dihydropyridine Calcium Channel Blocker. The mechanism of action of clevidipine is as a Calcium Channel Antagonist.
응용 분야
용도Antihypertensive.
공급사50 곳
관련 반응
연결된 노트
불러오는 중…